輝瑞為未來增長調(diào)整組織架構(gòu)

2018年7月11日紐約——輝瑞公司今天宣布將公司重組為三塊業(yè)務(wù)：基于科學(xué)的創(chuàng)新藥品業(yè)務(wù)（生物類似藥和專注于抗感染及無菌注射劑產(chǎn)品的醫(yī)院業(yè)務(wù)部也將包括在內(nèi)）；專注于過專利期品牌藥及仿制藥、并在輝瑞內(nèi)部擁有相當(dāng)自主性的成熟藥品業(yè)務(wù)；以及健康藥物業(yè)務(wù)。這些變化將于2019財(cái)年開始生效。

“這一新架構(gòu)反映了這些業(yè)務(wù)的自然演進(jìn)。這是基于我們已上市產(chǎn)品和即將上市的在研產(chǎn)品的持續(xù)走強(qiáng)，以及樂瑞卡在美國市場2018年12月（或之后）專利到期后，預(yù)計(jì)2020年以后由于專利到期所造成的影響將大幅降低。我們預(yù)計(jì)2020年之后將有更快和更持續(xù)的業(yè)務(wù)收入增長組合。在此過渡期間，我們認(rèn)為這一新架構(gòu)將使各塊業(yè)務(wù)更好地定位以達(dá)到其增長潛力。”輝瑞公司董事長兼首席執(zhí)行官晏瑞德（Ian Read）表示。

創(chuàng)新藥品業(yè)務(wù)將包括輝瑞目前所有輝瑞創(chuàng)新醫(yī)療業(yè)務(wù)部門，以及一個新的經(jīng)營輝瑞全球無菌注射劑和抗感染藥品組合的醫(yī)院藥品業(yè)務(wù)部。這將使我們更加專注和以用戶為中心。同時輝瑞還會將生物類似藥、腫瘤、炎癥及免疫業(yè)務(wù)并入創(chuàng)新藥品業(yè)務(wù)。這些業(yè)務(wù)部門在其各自治療領(lǐng)域都具備很強(qiáng)的醫(yī)學(xué)、商務(wù)和患者體驗(yàn)方面的能力，將為這些藥品提供一個強(qiáng)大的商業(yè)化平臺。

人口老齡化帶來的對新的創(chuàng)新藥物日益增長的需求和生物技術(shù)快速發(fā)展帶來的突破性治療方案是創(chuàng)新藥品業(yè)務(wù)迅猛增長的基礎(chǔ)。輝瑞相信，基于強(qiáng)勁的增長中的上市產(chǎn)品組合、2020年開始預(yù)期的新一波新品上市，輝瑞的創(chuàng)新藥品業(yè)務(wù)正蓄勢待發(fā)。

成熟藥品業(yè)務(wù)將包括輝瑞大部分專利到期固體口服藥物品牌，如樂瑞卡、立普妥、絡(luò)活喜、萬艾可等，以及某些仿制藥。這塊業(yè)務(wù)將在世界各區(qū)域運(yùn)營。為了讓該業(yè)務(wù)行動迅速和靈活，它將有其自己獨(dú)有和專職的生產(chǎn)、市場、法規(guī)職能，在一些例外情況下還包括支持部門，這將提高其自主性并在輝瑞內(nèi)部像一個真正獨(dú)立的部門運(yùn)作。

在樂瑞卡于2018年12月（或之后）在美國的專利到期所預(yù)期造成的影響過后，輝瑞預(yù)計(jì)成熟藥品業(yè)務(wù)收入有潛力產(chǎn)生可持續(xù)的適度增長。新興市場，尤其是亞洲的城市化和中產(chǎn)階級的興起提供了額外的準(zhǔn)入機(jī)會以及對成熟的品牌藥和仿制藥的強(qiáng)勁需求。作為在亞洲，尤其是在中國的制藥公司，我們相信輝瑞具有在這一重要和快速發(fā)展的市場上的優(yōu)勢。

“為全球患者提供關(guān)鍵藥物仍然是我們在輝瑞工作的指南。這一新的架構(gòu)設(shè)計(jì)能使我們在多元化的市場里更加專注于多元化的患者。”輝瑞首席運(yùn)營官艾伯樂(Albert Bourla)表示。“此外，這一架構(gòu)將使成熟藥品業(yè)務(wù)能化其特有的增長機(jī)會，同時提供在未來抓住提升其價(jià)值的各種機(jī)會的靈活性。”

健康藥物業(yè)務(wù)將包括所有輝瑞非處方藥產(chǎn)品，將繼續(xù)相對自主地運(yùn)營，并將有其專門的生產(chǎn)和法規(guī)職能。

健康藥物業(yè)務(wù)基礎(chǔ)增長強(qiáng)勁，同時又與其他兩塊處方藥業(yè)務(wù)有所不同。消費(fèi)者主義的趨勢以及不斷增長的對持續(xù)健康的專注使消費(fèi)者尋求易于獲得的健康和養(yǎng)生解決方案。擁有一個強(qiáng)大的橫跨健康和養(yǎng)生領(lǐng)域的全球品牌組合，公司相信該業(yè)務(wù)能很好地保持其增長。輝瑞將繼續(xù)評估該業(yè)務(wù)的戰(zhàn)略選擇并預(yù)期在2018年內(nèi)做出決定。

這些組織架構(gòu)的變化預(yù)計(jì)不會影響目前的資源分配重點(diǎn)和2018財(cái)政年度的財(cái)務(wù)指南。基于2017年的實(shí)際結(jié)果，創(chuàng)新藥品業(yè)務(wù)（包括健康藥物）預(yù)計(jì)將占輝瑞總收入的四分之三，成熟藥品業(yè)務(wù)將占大約四分之一。輝瑞將在2019一季度財(cái)報(bào)發(fā)布時提供反映這一新架構(gòu)的財(cái)務(wù)報(bào)告。

當(dāng)這些調(diào)整生效時，黃瑋明（Angela Hwang）和楊宇翰(John Young) 將分別領(lǐng)導(dǎo)輝瑞創(chuàng)新藥品業(yè)務(wù)的不同部分，并向艾伯樂匯報(bào)。

楊宇翰，集團(tuán)總裁，將負(fù)責(zé)內(nèi)科藥品、腫瘤（包括生物類似藥）和罕見病業(yè)務(wù)部門。此外，他還將負(fù)責(zé)在所有新興市場的創(chuàng)新藥品業(yè)務(wù)。

黃瑋明，集團(tuán)總裁，將負(fù)責(zé)炎癥及免疫（包括生物類似藥）、疫苗和醫(yī)院藥品業(yè)務(wù)部。此外，她還將領(lǐng)導(dǎo)輝瑞健康藥物業(yè)務(wù)。

成熟藥品業(yè)務(wù)將由Michael Goettler領(lǐng)導(dǎo)，他將成為輝瑞執(zhí)行管理團(tuán)隊(duì)成員并向艾伯樂匯報(bào)。Goettler先生有著23年從業(yè)經(jīng)驗(yàn)，他在2007年隨著對惠氏的收購而加入輝瑞。之后擔(dān)任過一系列職責(zé)日益重要的高級管理職務(wù)，涉及普藥、特藥等多個治療領(lǐng)域。Goettler先生有著豐富的業(yè)務(wù)管理經(jīng)驗(yàn)并在多個市場和區(qū)域生活和工作過，包括亞太和歐洲。他負(fù)責(zé)輝瑞罕見病業(yè)務(wù)并推動公司涉足基因治療領(lǐng)域。他現(xiàn)任輝瑞炎癥及免疫全球總裁。Goettler先生畢業(yè)于德國Koblenz企業(yè)管理學(xué)院并擁有德克薩斯大學(xué)MBA學(xué)位。

以上架構(gòu)變化取決于和各地員工組織或工會的協(xié)商，以及其他法律要求。

DISCLOSURE NOTICE: The information contained in this release is as of July 11, 2018. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about, among other things, Pfizer, its expected growth profile, its plans to organize the company into a new structure consisting of three businesses and the anticipated performance of those businesses, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, risks related to the ability to realize the anticipated benefits of the organization of the company into the new structure, including the possibility that the expected benefits from the new structure will not be realized or will not be realized within the expected time period; the risk that the businesses will not be organized into the new structure successfully; the potential for disruption from the organization of the company into the new structure and diversion of management’s attention from other aspects of our business as a result of the organization into the new structure; significant transaction costs; other business effects, including the effects of industry, market, economic, political or regulatory conditions; future exchange and interest rates; changes in tax and other laws, regulations, rates and policies; future business combinations or disposals; the uncertainties inherent in research and development, including the ability to meet anticipated trial commencement and completion dates and regulatory submission dates, as well as the possibility of unfavorable clinical trial results, including unfavorable new clinical data and additional analyses of existing clinical data; whether and when any drug applications may be filed in any jurisdictions for any pipeline assets or new indications for marketed products; whether and when regulatory authorities may approve any such applications, which will depend on its assessment of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted and, if approved, whether they will be commercially successful; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of the company’s pipeline assets or marketed products; competitive developments; risks and uncertainties related to our evaluation of strategic alternatives for our Consumer Healthcare business, including, among other things, the ability to realize the anticipated benefits of any strategic alternatives we may pursue for our Consumer Healthcare business, the potential for disruption to our business and diversion of management’s attention from other aspects of our business, the possibility that such strategic alternatives will not be completed on terms that are advantageous to Pfizer, the possibility that we may be unable to realize a higher value for our Consumer Healthcare business through strategic alternatives, and unknown liabilities. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.